New EMA guidance available for Parkinsons and Diabetes, CF endpoint workshop dates announced

In the past few weeks the European Medicines Agency has released updated guidance in a number of disease areas, including Parkinsons and diabetes, and they have published the dates of a workshop to discuss endpoints in development of new drugs … Continue reading

Antithrombotics and diabetes treatments responsible for most emergency adverse drug events: NEJM

In an article published in the New England Journal of Medicine (NEJM) on 24 November 2011, the authors report that in older Americans, warfarin is the drug that is most commonly responsible for emergency hospital admissions related to drug side effects.  … Continue reading

Albiglutide doesn’t match Victoza in phase 3 diabetes trial

GlaxoSmithKline (GSK) announced on 16 November 2011, that albiglutide did not meet its primary endpoint of non-inferiority compared with liraglutide (Victoza, Novo Nordisk) in the HARMONY 7 trial – a head-to-head comparison of the 2 GLP-1 agonists, and the first of 8 phase … Continue reading